Oyster Point Pharma Announces Addition to the Russell 2000®, Russell 3000® and Russell Microcap® Indexes
23 déc. 2019 09h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma to Present at the 38th Annual J.P. Morgan Healthcare Conference
17 déc. 2019 08h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights
03 déc. 2019 07h00 HE
|
Oyster Point Pharma, Inc.
ZEN Phase 1 top-line data Closed IPO financing and received $92.0 million in gross proceeds PRINCETON, N.J., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a...
Oyster Point Pharma to Present at the 31st Annual Piper Jaffray Healthcare Conference
25 nov. 2019 08h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma Announces Positive Top-Line Results From the Phase 1 “ZEN” Study of Its Lead Nicotinic Agonist Nasal Spray in Development for the Treatment of Dry Eye Disease
22 nov. 2019 17h12 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma Announces Closing of Initial Public Offering
05 nov. 2019 09h10 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class...
Oyster Point Pharma Announces Pricing of Initial Public Offering
30 oct. 2019 20h17 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class...